{"nctId":"NCT04491994","briefTitle":"Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression","startDateStruct":{"date":"2020-04-10","type":"ACTUAL"},"conditions":["Covid19","Progression"],"count":540,"armGroups":[{"label":"Standard of Care (SOC)","type":"NO_INTERVENTION","interventionNames":[]},{"label":"HCQ arm","type":"EXPERIMENTAL","interventionNames":["Drug: HCQ"]}],"interventions":[{"name":"HCQ","otherNames":["HCQ + Standard of Care (SOC)"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Mild Corona virus disease (COVID-19)\n* PCR confirmed infection\n* Hospital admitted patients\n\nExclusion Criteria:\n\n* Moderate, severe and critical COVID-19\n* day 0 CRP greater than 6mg/dl, ALC \\< 1000 or evidence of infiltrates on X-ray chest\n* comorbidity with life expectancy less than 6 months\n* Contraindications to HCQ therapy","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Progression","description":"After start of treatment, development of fever \\> 101 F for \\> 72 hours, shortness of breath by minimal exertion (10-Step walk test), derangement of basic lab parameters (ALC \\< 1000 or raised CRP) or appearance of infiltrates on CXR during course of treatment was labeled as progression irrespective of PCR status","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Viral Clearance","description":"PCR negativity on day 7 and 14 after admission","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":151},"commonTop":[]}}}